MDRP Session Spotlight: Effect of Acquisitions and Divestiture on MDRP Operations for Large Pharma Manufacturers

Today's post is authored by Miree Lee, Principal, M. LEE CONSULTI NG

In a period of mergers, acquisitions, product divestitures and product acquisitions (collectively, "Transactions"), it can be a challenging and exciting time for the parties involved. However, amidst the excitement and closing of the "deal", those of us in GP, both on the buyer and seller side, need to be mindful of the government pricing obligations and government program contract administration associated with such Transactions.

Speaker Miree Lee

During "Effect of Acquisitions and Divestiture on MDRP Operations for Large Pharma Manufacturers" session, we will examine GP involvement in the deal negotiation process, critical data exchanges between the parties, obligations of the seller vs. buyer, different manners in which pricing calculations, submissions, and certifications are handled between the buyer and seller, how obligations may differ by government price type, government agency notifications, pitfalls and lessons learned from past experience, and so much more.

If your company is considering a merger, acquisition, product divestiture or product acquisition, be sure not to miss this session!  If you'd like to know more about this session and the rest of the agenda, download the agenda here.  If you'd like to join us in Chicago for the Medicaid Drug Rebate Program Summit this September 10-12, register to join us today and mention XP1758BLOG to save 25% off the standard rate.

Featured Session: Effect of Acquisitions and Divestiture on MDRP Operations for Large Pharma Manufacturers

Featured Speakers: 
Moderator: Miree Lee, Principal, M. LEE CONSULTI NG
Brad Wallner, Government Pricing Specialist,, GRIFOLS, INC.
Sanjida Chowdhury, Director, Business Government Analysis, APP PHARMACEUTICALS
Peggy Watson, Medicaid Drug Rebate Manager, AMGEN
Elizabeth Greco, Director, Government Pricing, PFIZER

About the session: 
While changing a company’s portfolio has numerous benefits, for large pharma, with thousands of NDCs, adding or subtracting a company’s portfolio can be a daunting task. For acquisitions especially, bringing a company’s products into the fold and dealing with their pricing and contracts can be a headache if the company didn’t have enough functionality. In this session, large pharma
insiders describe how their company handled an acquisition or divestiture.